Sclerosol Intrapleural Aerosol
Company: Bryan CorporationApproval Status: Approved January 1998
Treatment for: malignant pleural effusions
Areas: Cancer & Oncology; Respiratory
General Information
Sclerosol Intrapleural Aerosol has been approved for the prevention of recurrence of malignant pleural effusions in symptomatic patients. Symptoms include chest pain, dyspnea, and coughing. It is to be administered by aerosol during thracoscopy or open thoracotomy.
Sclerosol Intrapleural Aerosol Drug Information
The Sclerosol Intrapleural Aerosol drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
